My survival is based on research. With limited NIH funding, I fear that my life, and the lives of others, will be left ...

UCART22 Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025; Orphan Drug Designation (ODD) and Rare ...

Another male patient with blood cancer had been administered approximately twice the prescribed dose of Fludarabine, another chemotherapy drug, for three consecutive days. In early March ...

Q4 2024 Earnings Call Transcript March 13, 2025 Allogene Therapeutics, Inc. beats earnings expectations. Reported EPS is ...

Momentum Builds Across Programs with Key Data Milestones Expected in 2025Cemacabtagene Ansegedleucel (Cema-Cel): First-Line (1L) Consolidation in ...

Anthony Stein, MD, assessed total marrow and lymphoid irradiation with post-transplant cyclophosphamide in patients with ...

Christopher L. Moertel, MD, University of Minnesota, discusses the trial data that helped get mirdametinib approved and what providers can do to keep measuring quality of life (QOL) improvements.

Acute myelogenous leukemia (AML) is seen in this stock image. Duke researchers have discovered a new combination of drugs that is more effective than chemotherapy at killing acute myeloid leukemia ...

Allogene Therapeutics reported a narrower-than-expected loss for Q4 2024, with an EPS of -$0.28, surpassing the forecast of -$0.32. The company’s stock responded positively, rising 3.66% in ...